Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$108.70 USD

108.70
9,520,162

-1.05 (-0.96%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

J&J Stock Up This Year So Far: Will the Momentum Continue?

by Zacks Equity Research

J&J (JNJ) performs better than the industry in 2019 so far and looks well poised to sustain the momentum in the rest of the year.

Sweta Killa headshot

Dow on Longest Losing Streak in 8 Yrs: 5 Stocks Still Up in ETF

by Sweta Killa

The Dow Jones fell for a fifth straight week - representing the longest losing streak since June 2011 on intensifying trade dispute. Though most of the stocks in the fund's portfolio pushed the dow ETF down, a few are still in green.

Incyte (INCY) Receives FDA Nod for Label Expansion of Jakafi

by Zacks Equity Research

Incyte (INCY) obtains FDA approval for a third indication of lead drug, Jakafi, for the treatment of GVHD.

Glaxo's Shingles Vaccine Shingrix Gets Approval in China

by Zacks Equity Research

GlaxoSmithKline (GSK) plans to launch Shingrix in China in several phases starting 2020.

Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary

by Zacks Equity Research

Nektar (NKTR) forms wholly-owned subsidiary, Inheris Biopharm, focusing on CNS pipeline. The subsidiary will mainly be responsible for potential commercialization of under review pain drug, NKTR-181.

Kinjel Shah headshot

Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates

by Kinjel Shah

Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.

Swarup Gupta headshot

Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics

by Swarup Gupta

The index suffered a difficult week as investors braced for a protracted U.S.-China trade war.

Synlogic (SYBX) Enters Cancer Collaboration with Roche

by Zacks Equity Research

Synlogic (SYBX) announces clinical collaboration with Roche to develop its pre-clinical cancer candidate in combination with Roche's PD-L1 inhibitor, Tecentriq.

J&J's Invokana sNDA Gets Priority Review Status From FDA

by Zacks Equity Research

FDA grants priority review to J&J's (JNJ) Invokana sNDA for the treatment of chronic kidney disease in patients with type II diabetes

Array BioPharma Gains on Colorectal Cancer Study Success

by Zacks Equity Research

Array BioPharma's (ARRY) phase III study, evaluating the Braftovi triplet for treating metastatic colorectal cancer, meets the primary goal of ORR and OS. Shares rally.

Company News For May 22, 2019

by Zacks Equity Research

Companies In The News Are: KSS,AZO,HD,MRK

Merck to Buy Private Cancer Drugmaker Peloton Therapeutics

by Zacks Equity Research

Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.

Merck's Keytruda Fails in Late-Stage Breast Cancer Study

by Zacks Equity Research

Merck's (MRK) Keytruda fails in a late-stage study evaluating it as second- or third-line treatment for breast cancer.

Why Merck (MRK) is a Great Dividend Stock Right Now

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

AbbVie's Brain Cancer Candidate Fails in Phase III Study

by Zacks Equity Research

AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs

by Kinjel Shah

FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs

ImmunoGen Plunges as FDA Recommends New Study for Lead Drug

by Zacks Equity Research

FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.

Sweta Killa headshot

Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?

by Sweta Killa

Style Box ETF report for FTCS

Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer

by Zacks Equity Research

Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.

Nalak Das headshot

4 Dow Stocks to Buy on the Dip Despite Market Volatility

by Nalak Das

After an impressive bull run in the first four months of this year, it seems volatility is once again ready to rear its ugly face in Wall Street.

Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer

by Zacks Equity Research

Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.

What's in Store for Affimed (AFMD) This Earnings Season?

by Zacks Equity Research

Affimed (AFMD) is likely to provide update on the progress of its pipeline candidates when its reports first-quarter results.

Endo (ENDP) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Endo's (ENDP) earnings and revenues top expectations in the first quarter of 2019.

Kinjel Shah headshot

Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug

by Kinjel Shah

Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.

Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Intercept's (ICPT) Q1 revenues top estimates on strong Ocaliva sales, driven by sales force expansion.